NCT00308854已完成3 期
PD P 506 A or Its Placebo in Combination With Red Light for Photodynamic Therapy of Mild to Moderate Actinic Keratosis
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 107
- 试验地点
- 14
- 主要终点
- Complete clinical clearance rate (CCR) of treated actinic keratosis lesions 12 weeks after PDT
研究概览
简要总结
The aim of this study is to investigate whether PD P 506 A-PDT is effective in treating mild to moderate AK lesions located on the head.
详细描述
Actinic keratosis (AK) is a pre-cancerous skin abnormality usually caused by sun exposure. Actinic keratoses occur most commonly in fair skin, especially in the elderly. They mainly occur in sun-exposed skin areas like head and hands. It is standard of care to remove AK when diagnosed, which can be achieved by either physical ablation, chemotherapeutic agents or photodynamic therapy (PDT). A direct comparison versus placebo which is necessary for the exact quantification of the effect of PD P 506 A has not yet been performed and is subject of this study protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Caucasian patients
- •Diagnosis of actinic keratosis (AK) with at least three locally separated lesions located on head and/or face (hairless areas)
- •Selected AK study lesions have clearly defined margins and are mild to moderate
- •The distance between the study lesion borders is > 1.0 cm
- •Maximum diameter of each study lesion is 1.8 cm
- •Skin sun sensitivity type I to IV according to Fitzpatrick
排除标准
- •PDT Non-responder
- •Pre-treatment of the AK lesions eligible for study procedures with pharmaceuticals approved for the treatment of AK during the 4 weeks preceding PDT
- •Pre-treatment of the AK lesions eligible for study procedures during the 2 weeks preceding PDT with keratolytic agents e.g. TCA, urea or salicylic acid containing formulations
- •Pre-treatment with hypericin during the 2 weeks preceding PDT
- •Treatment with systemic retinoids during the 3 months preceding PDT
- •Treatment with cytostatics or radiation during the 3 months preceding PDT
- •Female patients of childbearing potential
- •Patients with clinically relevant suppression of the immune system
- •Diagnosis of Porphyria
- •Skin diseases that might interfere with response evaluation of study PDT
- •Skin sun sensitivity type V or VI according to Fitzpatrick
- •Known intolerance to one or more of the ingredients of the study medication
- •Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written informed consent
- •Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion
- •Suspected lack of compliance
结局指标
主要结局
Complete clinical clearance rate (CCR) of treated actinic keratosis lesions 12 weeks after PDT
时间窗: 12 weeks
次要结局
- Adverse events/reactions and local reactions during application of the study medication as well as during and after study therapy(12 months)
- Satisfaction and independent cosmetic rating of the cleared study lesions by patient and investigator in case of successful clearance and no recurrence of the lesion(12 months)
- CCR on patient basis 12 weeks, 6, 9 and 12 months after PDT(12 months)
- CCR of treated actinic keratosis lesions 6, 9 and 12 months after PDT(12 months)
研究者
研究点 (14)
Loading locations...
相似试验
进行中（未招募）
不适用
PD P 506 A or its placebo in combination with red light for photodynamic therapy of mild to moderate actinic keratosisActinic keratosisEUCTR2005-003555-13-DEphotonamic GmbH & Co. KG90
已完成
2 期
An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial CystitisInterstitial CystitisPainful Bladder SyndromeNCT00739739Pfizer161
终止
2 期
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.Ulcerative ColitisNCT03269695Pfizer20
终止
2 期
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary SarcoidosisPulmonary SarcoidosisNCT01732211Pfizer1
已完成
2 期
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT02958865Pfizer319